XORTX Therapeutics Files February 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Feb 24, 2025 · CIK: 1729214
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
XORTX files Feb 2025 6-K, confirms 20-F reporting, CEO Davidoff signs off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on February 24, 2025, to report for the month of February 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The report was signed by CEO Allen Davidoff.
Why It Matters
This filing serves as an update for investors regarding the company's reporting status and confirms its adherence to SEC regulations for foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- February 24, 2025 (date) — Filing date
- 20250224 (date) — Conformed period of report
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
Which form will XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
The Form 6-K filing was signed by Allen Davidoff, Chief Executive Officer.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is February 24, 2025.
What is the company's principal business address?
The company's principal business address is 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 24, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).